Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing innovative therapies, today announced that they have obtained Japan Country Patent No. 7677628 for the ...

Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases. By Hoth Therapeutics, Inc. Jun 12, 2025 Jun 12, 2025 Updated Jun 12, 2025; ...

In particular, rare disease biotechs and those developing complex modalities like cell and gene therapies have urged the Trump administration to provide exemptions to pending pharma tariffs. The pleas ...

Blueprint Medicines Corporation focuses on Ayvakit, BLU-808, and Elenestinib with strong potential in mast cell disorders. Read why BPMC stock is a strong buy.

Systemic mastocytosis is a rare disorder causing excessive mast cell buildup in organs. Learn about symptoms, types, causes, diagnosis, and treatments that improve life expectancy.

Mast cell activation syndrome, or disease (MCAS), is a condition that causes mast cells to release these substances too frequently, resulting in severe allergic reactions. After detecting an ...

Mast cells contain granules packed with over 200 signaling chemicals including histamine, prostaglandins, leukotrienes and cytokines. When functioning properly, they release these substances in ...

Poster Presentation: Identification of Clonal Mast Cell Disease in Patients with Anaphylaxis or Evidence of Systemic Mast Cell Activation: A Post Hoc Analysis from PROSPECTOR (Abstract 301 ...

Systemic mastocytosis is a disease where too many abnormal mast cells (a type of white blood cell) build up in your skin and other organs. You might get a variety of symptoms, including itchy skin ...

Eosinophils and mast cells are two types of immune cells with critical roles in responding to foreign assaults. When these cells do not function properly, several disease outcomes can develop (e.g.

Mast cell activation can be triggered by various factors, such as certain foods, environmental allergens, and stress. Identifying and avoiding these triggers can help reduce the frequency of symptoms.

A desperate dad becomes a beacon in the rare-disease world. Terry Pirovolakis isn’t a scientist or a doctor. He isn’t wealthy. He’s a 45-year-old IT professional, with three children and a ...